1. Quintans-Júnior LJ, Araújo AA, Brito RG, Santos PL, Quintans JS, Menezes PP, Serafini MR, Silva GF, Carvalho FM, Brogden NK, Sluka KA. β-caryophyllene, a dietary cannabinoid, complexed with β-cyclodextrin produced anti-hyperalgesic effect involving the inhibition of Fos expression in superficial dorsal horn. Life Sciences. 2016. Mar 15;149:34-41. PMID 26883973
  2. Kelchen MN, Siefers KJ, Converse CC, Farley MJ, Holdren GO, Brogden NK. Micropore closure kinetics are delayed following microneedle insertion in elderly subjects. Journal of Controlled Release. 2016. Mar 10;225:294-300. PMID 26829102
  3. Leelakanok N, Fischer CL, Bates AM, Guthmiller JM, Johnson GK, Salem AK, Brogden KA, Brogden NK. Cytotoxicity of HBD3 for dendritic cells, normal human epidermal keratinocytes, hTERT keratinocytes, and primary oral gingival epithelial keratinocytes in cell culture conditions. Toxicology Letters. 2015. Dec 3;239(2):90-6. PMID 26367466
  4. Kinn PM, Holdren GO, Westermeyer BA, Abuissa M, Fischer CL, Fairley JA, Brogden KA, Brogden NK. Age-dependent variation in cytokines, chemokines, and biologic analytes rinsed from the surface of healthy human skin. Scientific Reports. 2015. Jun 2;5:10472. PMID 26035055
  5. Holdren GO, Rosenthal D, Yang J, Bates A, Fischer C, Zhang Y, Brogden NK, and Brogden KA. Antimicrobial activity of chemokine CXCL10 for dermal and oral microorganisms. Antibiotics. 2014. 3(4):527-539. PMID 25859394
  6. Kelchen MN, Holdren GO, Farley MJ, Zimmerman BM, Fairley JA, Brogden NK. Optimization of impedance spectroscopy techniques for measuring cutaneous micropore formation after microneedle treatment in an elderly population. Pharmaceutical Research. 2014. Dec;31(12):3478-86. PMID 24947437
  7. Ghosh P, Brogden NK, Stinchcomb AL. Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle treated skin. Journal of Pharmaceutical Sciences. 2014. Feb;103(2):652-60. PMID 24395718
  8. Ghosh P, Brogden NK, Stinchcomb AL. Effect of formulation pH on transport of naltrexone species and pore closure in microneedle-enhanced transdermal drug delivery. Molecular Pharmacology. 2013. Jun 3;10(5):2331-9. PMID 23590208
  9. Milewski M, Paudel KS, Brogden NK, Ghosh P, Banks SL, Hammell DC, Stinchcomb AL. Microneedle-assisted percutaneous delivery of naltrexone hydrochloride in Yucatan minipig: in vitro – in vivo correlation. Molecular Pharmaceutics. 2013. Oct 7;10(10):3745-3757. PMID 24053426
  10. Brogden NK, Banks SL, Crofford LJ, Stinchcomb AL. Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans. Pharmaceutical Research. 2013. Aug;30(8):1947-55. PMID 23761054
  11. Brogden NK, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. Development of in vivo impedance spectroscopy techniques for measurement of micropore formation following microneedle insertion. 2013. Journal of Pharmaceutical Sciences. Jun;102(6):1948-56. PMID 23589356
  12. Brogden NK, Milewski M, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. Diclofenac delays micropore closure following microneedle treatment in human subjects. Journal of Controlled Release. 2012. Aug;16(3):220-29. PMID 22929967
  13. Brogden NK, Mehalick L, Fischer CL, Wertz PW, Brogden KA. Review - The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation. Skin Pharmacology and Physiology. 2012. 25(4):167-81. PMID 22538862
  14. Brogden NK, Brogden KA. Review - Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?  International Journal of Antimicrobial Agents. 2011. Sep;38(3):217-25. PMID 21733662
  15. Banks SL, Paudel KS, Brogden NK, Loftin CD, Stinchcomb AL. Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharmaceutical Research. 2011. May;28(5):1211-9. PMID 21301935
  16. Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in transdermal delivery. Therapeutic Delivery. 2010. Jul;1(1):109-131.
  17. Banks SL, Pinninti RR, Gill HS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs in vivo. Journal of Pharmaceutical Sciences. 2010. Jul;99(7):3072-80. PMID 20166200
  18. Milewski M, Brogden NK, Stinchcomb AL. Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. Expert Opinion on Drug Delivery. 2010. May;7(5):617-29. PMID 20205604
  19. Florang VF, Rees JR, Brogden NK, Anderson DG, Hurley TD, and Doorn JA. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Neurotoxicology. 2007. Jan;28(1):76-82. PMID 16956664